496 related articles for article (PubMed ID: 26016605)
1. Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration.
Fauser S; Viebahn U; Muether PS
Acta Ophthalmol; 2015 Dec; 93(8):734-8. PubMed ID: 26016605
[TBL] [Abstract][Full Text] [Related]
2. Profile of intraocular immune mediators in patients with age-related macular degeneration and the effect of intravitreal bevacizumab injection.
Agawa T; Usui Y; Wakabayashi Y; Okunuki Y; Juan M; Umazume K; Kezuka T; Takeuchi M; Yamauchi Y; Goto H
Retina; 2014 Sep; 34(9):1811-8. PubMed ID: 24801651
[TBL] [Abstract][Full Text] [Related]
3. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
[TBL] [Abstract][Full Text] [Related]
4. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
5. The Intraocular Cytokine Profile and Therapeutic Response in Persistent Neovascular Age-Related Macular Degeneration.
Rezar-Dreindl S; Sacu S; Eibenberger K; Pollreisz A; Bühl W; Georgopoulos M; Krall C; Weigert G; Schmidt-Erfurth U
Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):4144-50. PubMed ID: 27537264
[TBL] [Abstract][Full Text] [Related]
6. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration.
Muether PS; Hermann MM; Dröge K; Kirchhof B; Fauser S
Am J Ophthalmol; 2013 Nov; 156(5):989-993.e2. PubMed ID: 23938122
[TBL] [Abstract][Full Text] [Related]
7. Angiogenin, FGF-α, and IL-36β have higher expression levels in aqueous humor of nAMD patients in comparison to cataract patients.
Chen K; Xu W; Zheng J; Shen Y; Ma J; Chen Z
BMC Ophthalmol; 2020 Oct; 20(1):431. PubMed ID: 33115414
[TBL] [Abstract][Full Text] [Related]
8. Short-term effect of intravitreal ranibizumab on intraocular concentrations of vascular endothelial growth factor-A and pigment epithelium-derived factor in neovascular glaucoma.
Wang JW; Zhou MW; Zhang X; Huang WB; Gao XB; Wang W; Chen S; Zhang XY; Ding XY; Jonas JB
Clin Exp Ophthalmol; 2015 Jul; 43(5):415-21. PubMed ID: 25488632
[TBL] [Abstract][Full Text] [Related]
9. Cytokine and Chemokine Profile Changes in Patients with Neovascular Age-Related Macular Degeneration After Intravitreal Ranibizumab Injection for Choroidal Neovascularization.
Sun T; Wei Q; Gao P; Zhang Y; Peng Q
Drug Des Devel Ther; 2021; 15():2457-2467. PubMed ID: 34140764
[TBL] [Abstract][Full Text] [Related]
10. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
[TBL] [Abstract][Full Text] [Related]
11. Long-term alterations of systemic vascular endothelial growth factor levels in patients treated with ranibizumab for age-related macular degeneration.
Enders P; Muether PS; Hermann M; Ristau T; Fauser S
Retina; 2015 Mar; 35(3):454-8. PubMed ID: 25170863
[TBL] [Abstract][Full Text] [Related]
12. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times.
Fauser S; Muether PS
Br J Ophthalmol; 2016 Nov; 100(11):1494-1498. PubMed ID: 26888975
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
Muether PS; Hermann MM; Viebahn U; Kirchhof B; Fauser S
Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
[TBL] [Abstract][Full Text] [Related]
14. Intraocular Vascular Endothelial Growth Factor Levels in Pachychoroid Neovasculopathy and Neovascular Age-Related Macular Degeneration.
Hata M; Yamashiro K; Ooto S; Oishi A; Tamura H; Miyata M; Ueda-Arakawa N; Takahashi A; Tsujikawa A; Yoshimura N
Invest Ophthalmol Vis Sci; 2017 Jan; 58(1):292-298. PubMed ID: 28114590
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of Inflammatory Factors in Aqueous Humor during Ranibizumab or Aflibercept Treatment for Age-Related Macular Degeneration.
Motohashi R; Noma H; Yasuda K; Kotake O; Goto H; Shimura M
Ophthalmic Res; 2017; 58(4):209-216. PubMed ID: 28796997
[TBL] [Abstract][Full Text] [Related]
16. A model of the ocular pharmacokinetics involved in the therapy of neovascular age-related macular degeneration with ranibizumab.
Saunders DJ; Muether PS; Fauser S
Br J Ophthalmol; 2015 Nov; 99(11):1554-9. PubMed ID: 25957377
[TBL] [Abstract][Full Text] [Related]
17. Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration.
Arai Y; Takahashi H; Inoda S; Tan X; Sakamoto S; Inoue Y; Fujino Y; Kawashima H; Yanagi Y
PLoS One; 2020; 15(3):e0229342. PubMed ID: 32155173
[TBL] [Abstract][Full Text] [Related]
18. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.
Wang X; Sawada T; Sawada O; Saishin Y; Liu P; Ohji M
Am J Ophthalmol; 2014 Oct; 158(4):738-744.e1. PubMed ID: 24973606
[TBL] [Abstract][Full Text] [Related]
19. Aqueous humor cytokine levels in patients with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration.
Sakurada Y; Nakamura Y; Yoneyama S; Mabuchi F; Gotoh T; Tateno Y; Sugiyama A; Kubota T; Iijima H
Ophthalmic Res; 2015; 53(1):2-7. PubMed ID: 25472810
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept.
Sato T; Enoki T; Karasawa Y; Someya H; Taguchi M; Harimoto K; Takayama K; Kanda T; Ito M; Takeuchi M
Front Immunol; 2021; 12():738521. PubMed ID: 34721402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]